Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5 million shares at $20.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to advance development of its pipeline candidates NXP100, NXP200, and NXP900, hire personnel, and cover operational expenses. The offering is expected to close on July 1, 2026.